Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
11.61
+0.52 (4.69%)
At close: Jun 15, 2026, 4:00 PM EDT
11.35
-0.26 (-2.24%)
After-hours: Jun 15, 2026, 7:39 PM EDT
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 209.00K CHF in the quarter ending March 31, 2026, a decrease of -26.67%. This brings the company's revenue in the last twelve months to 1.12M, up 50.07% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth.
Revenue (ttm)
1.12M CHF
Revenue Growth
+50.07%
P/S Ratio
500.78
Revenue / Employee
18,733 CHF
Employees
60
Market Cap
701.11M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| CytomX Therapeutics | 35.54M |
| Evommune | 10.00M |
| Omeros | 9.89M |
| Allogene Therapeutics | 22.00K |
OCS News
- 4 days ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire
- 5 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 6 days ago - Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - GlobeNewsWire
- 7 days ago - Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 12 days ago - Oculis price target lowered to $23 from $42 at JPMorgan - TheFly
- 13 days ago - Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses - GlobeNewsWire
- 13 days ago - Oculis price target lowered to $38 from $49 at Baird - TheFly